Heidelberg Pharma (0QW5) Stock Overview
A biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
0QW5 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Heidelberg Pharma AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.10 |
| 52 Week High | €5.42 |
| 52 Week Low | €2.11 |
| Beta | 1.65 |
| 1 Month Change | -11.17% |
| 3 Month Change | -33.19% |
| 1 Year Change | n/a |
| 3 Year Change | -44.04% |
| 5 Year Change | -18.85% |
| Change since IPO | -88.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QW5 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 4.0% | 9.0% | 2.2% |
| 1Y | n/a | 9.8% | 13.4% |
Return vs Industry: Insufficient data to determine how 0QW5 performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0QW5 performed against the UK Market.
Price Volatility
| 0QW5 volatility | |
|---|---|
| 0QW5 Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: 0QW5's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0QW5's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 111 | Andreas Pahl | heidelberg-pharma.com |
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-201 for the treatment of colorectal cancer; and TAK-ATAC for the treatment of oncology.
Heidelberg Pharma AG Fundamentals Summary
| 0QW5 fundamental statistics | |
|---|---|
| Market cap | €144.94m |
| Earnings (TTM) | -€23.31m |
| Revenue (TTM) | €4.18m |
Is 0QW5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QW5 income statement (TTM) | |
|---|---|
| Revenue | €4.18m |
| Cost of Revenue | €520.65k |
| Gross Profit | €3.66m |
| Other Expenses | €26.97m |
| Earnings | -€23.31m |
Last Reported Earnings
May 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 87.55% |
| Net Profit Margin | -557.16% |
| Debt/Equity Ratio | 0% |
How did 0QW5 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 02:06 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/05/31 |
| Annual Earnings | 2024/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Heidelberg Pharma AG is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christian Weiz | Baader Helvea Equity Research |
| Bruno Bulic | Baader Helvea Equity Research |
| James Molloy | Caris & Company |